Journal of Clinical Endocrinology & Metabolism, Vol 69, 725-728, Copyright © 1989 by Endocrine Society

ARTICLES

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

E Ciccarelli, M Giusti, C Miola, F Potenzoni, D Sghedoni, F Camanni and G Giordano
Department of Biomedicine, University of Turin, Italy.

Cabergoline (CAB) is a new oral dopaminergic compound showing a very long-lasting PRL-lowering activity and reported to be well tolerated. The efficacy and tolerability of chronic treatment with CAB in 30 female hyperprolactinemic patients, aged 18-52 yr (6 microadenomas, 3 macroadenomas, and 21 functional hyperprolactinemias), were studied. In a group of 10 patients who received CAB (0.8 mg once weekly or 0.4 mg twice weekly) for 8 weeks PRL levels normalized while on treatment and remained normal (8 patients) or greatly reduced (1 patient) for 1-2 months after discontinuation of the drug. Twenty-six patients underwent chronic treatment (6-12 months) with an initial dose of 0.5 mg once weekly, subsequently increased to 1-2 mg in 10 patients and decreased in the other 2. Due to severe side-effects CAB was discontinued in 3 patients, in 1, 8, and 12 weeks. A significant reduction of PRL levels was already observed after the first week of treatment (mean +/- SEM basal values, 90.1 +/- 13.3 vs. 29.5 +/- 6.3 micrograms/L; P less than 0.001). Twenty-two patients had normal PRL levels in 1-36 weeks (mean, 6 weeks) with 0.5-2 mg CAB. Twenty-two patients resumed regular menses; 2 patients became pregnant after 3-11 months of treatment. Thirteen patients complained of side-effects (nausea, hypotension, headache, gastric pain, dizziness, and weakness) that disappeared with time in 10 of them. The comparison with a previous bromocriptine treatment regimen in 20 patients had shown that the number of patients requiring discontinuation of the latter drug was significantly higher (7 vs. 3 patients; P less than 0.001). However, 2 patients who needed to discontinue CAB were able to tolerate bromocriptine therapy. A computed tomographic scan performed after 12 months of therapy in 7 patients showed a significant reduction (50%) of the adenoma in 5. In conclusion, our results show that CAB is a well tolerated new dopamine agonist with long-lasting activity that represents an advance in chronic medical treatment of hyperprolactinemic conditions.

This article has been cited by other articles:

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				A. Barlier and P. Jaquet Quinagolide - a valuable treatment option for hyperprolactinaemia Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195. [Abstract] [Full Text] [PDF]

				A. Colao, A. Di Sarno, M. L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, R. Volpe, F. Di Salle, S. Cirillo, L. Annunziato, et al. Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2247 - 2252. [Abstract] [Full Text]

				J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts, P. Petrossians, P. Coremans, et al. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2518 - 2522. [Abstract] [Full Text]

				A. Colao, A. Di Sarno, M. L. Landi, S. Cirillo, F. Sarnacchiaro, G. Facciolli, R. Pivonello, M. Cataldi, B. Merola, L. Annunziato, et al. Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3574 - 3579. [Abstract] [Full Text] [PDF]

				A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, and G. Lombardi Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 876 - 883. [Abstract] [Full Text] [PDF]

				New drugs for hyperprolactinaemia DTB, September 1, 1995; 33(9): 65 - 67. [Abstract] [Full Text] [PDF]

				J. Webster, G. Piscitelli, A. Polli, C. I. Ferrari, I. Ismail, M. F. Scanlon, and The Cabergoline Comparative Study Group A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea N. Engl. J. Med., October 6, 1994; 331(14): 904 - 909. [Abstract] [Full Text]